This website sets cookies which are used to offer a personalized experience on our website, generate statistics, and realize advertising or social network tracking. Find out more about our Privacy & Cookie policy and how to manage them on your browser. You can change your cookie settings at any time.

ABSTRACT SUBMISSION IS NOW OPEN!

The INMC 2019 Program Committee invites the submission of abstracts on original work. Abstracts can be submitted for consideration for an oral or poster presentation. All successful abstracts will be published on the INMC 2019 website. Presenting authors must be registrants at the Conference. All abstracts must be submitted online via the conference website using the online submission form until September 24.

ABSTRACT KEY DATES

Abstract Submission Deadline: November 5, 2018
Presenter Notification: November 23, 2018
Presenter Registration Deadline: December 14, 2018
*Registration code for the abstract presenters will be sent directly after abstract submission.

 

ABSTRACT SUBMISSION NOTIFICATIONS

All notifications for regular abstract submission will be sent to the email address provided during the time of submission. Should you not have received the notification, please check your spam folder or contact the Conference Secretariat:

Shawn Cheng
info@nano-innovate.com
+1 604 909 1286


ABSTRACT SUBMISSION TOPICS

Clinical Nanomedicine and Regenerative Medicine (CNRM)▼
  • The future of healthcare and patient treatment options using nanomedicine and regenerative medicine therapies and diagnostics
  • Examples of clinical translation of nanomedicine and regenerative medicines progress to date
  • The evolving landscape of drug products containing nanomaterials
  • Should military personnel and athletes be considered morally eligible to have part of their bodies enhanced to increase their performance while people shouldn't?
  • Current status and perspective on nanomedicine-based therapies and regenerative medicines undergoing clinical trials
  • Gene-editing technologies and applications on FDA-regulated products
  • Innovative nano-approaches used to combine and/or enhance conventional chemo or radiation or other treatments
  • Brainstorm's clinical trials for ALS using mesenchymal stem cells (MSCs)
  • Bone Therapeutic orphan drug for osteonecrosis
  • The future of patient treatment options using cell-based immunotherapies composed of genetically-modified autologous T-cells
  • The importance of addressing the genotoxicity of nanomaterials and possible consequences for human health
Diagnostics and therapeutics▼
  • Nanotools and its future in medicine
  • Nanosensors for Medical Monitoring
  • In-vivo Nano-Imaging applications in cancer therapies
  • RNA-Targeting Therapies in Clinical Trials
  • Enzyvant investigational thymic-tissue based regenerative therapy
  • Adaptimmune cell therapy testing antigens expressed in a number of solid tumor cell types
  • Nanotherapeutic Drug Delivery
  • Clinical theragnostic for neuroendocrine carcinoid, neuroblastoma and medulloblastoma tumors
Infectious Diseases▼
  • Nanotechnology applications in Infectious Disease
  • Advances in nanomedicine drug delivery applications for HIV therapy
  • Nanomedicine detection and diagnostics
  • Evaluation of the Safety and Immunogenicity of a Recombinant Trivalent Nanoparticle Influenza Vaccine with Matrix M-1 Adjuvant (NanoFlu)
Nanoinformatics in Medicine▼
  • Data and metadata that would allow the integration of one dataset with another set of datasets
  • Challenges in informatics approaches for preclinical and clinical trial applications
  • Nanoinformatics Methodologies shared between Nanotoxicology and Environmental Toxicology
  • Experimental and nanoinformatics methods, data standards and data integration for medical toxicology, environmental toxicology and occupational health
  • Informatics approaches to improve research and product development in academia, clinical trials and commercialization
  • Differences in risk assessment between nanomedicine toxicology, environmental toxicology and occupational toxicology when there are high doses and acute exposure versus low doses and moderate exposure; respectively
  • Occupational hazardous informed risk assessment using dose responsive curves for worker exposure and offsite exposure
  • Opportunities and challenges in advancing nanoinformatics approaches for product development and clinical trials investigations
  • Tools and visualization technologies and techniques used in informatics for product development and clinical trials
Manufacturing Nanomedicine and Regenerative Medicines▼
  • Regenerative medicine manufacturing technologies using biofabrication for bioprinting
  • Clinical trial pipeline and commercial applications using nanoparticles to enhance tissue engineering
  • Advanced robotics and intelligent automation technologies in the manufacturing landscape
  • Partnering solution for cell therapy product development at corning
Advanced Informatics in Clinical Trials▼
  • Innovative statistical designs for biomarker enrichment considerations in oncology early development single-arm studies
  • The role of modeling & simulation on clinical trials
  • Statistical methods and machine-learning techniques for large-scaled data inference developed for treatment selection in precision medicine
  • Evaluate the application of nanotechnology on product characteristics, including stability and content uniformity
Fundamentals of Bio-distribution▼
  • Predicting Drug Safety and Efficacy
  • Stem Cells for Drug discovery, Toxicity Testing, and Disease Modeling
  • Nano-Toxicology
  • Environmental Toxicology
Global Health Impacts of Nanotechnology Law and Bioethics
  • Where are the regulations currently and where are the regulations going?
  • Addressing the legal implications for nano-enabled applications in medicine?
  • What are the global harmonization on nanomedicine products in commerce?
  • Bioethics concerns in nanomedicine and regenerative medicine?
Other

 


 

PRESENTATION METHODS ▼

During online abstract submission, authors will be requested to select their preferred method of presentation at the Conference.

Oral presentations - 15 minutes, excluding question time, in the Parallel Track sessions;

Poster session - 60 to 90-minute time periods throughout the Conference at which poster presenters are expected to attend.

Presentation method preferences will be taken into account during the review and program development process.

 


 

FORMAT & CONTENT GUIDELINES FOR SUBMITTING ABSTRACTS TO INMC 2019

Abstracts must be submitted via the website.

The Conference Secretariat is not able to accept abstracts submitted via email or fax. When submitting your abstract please follow the instructions listed below. 

ABSTRACT FORMAT GUIDELINES▼

The purpose of the abstract is to define the precise subject of the presentation to an audience.

Title: the abstract title should be a maximum of 140 characters, informative and contain major keywords.

Authors: On the online abstract submission form, it is required to enter the authors’ first names and surnames (indicating the presenting author) including the names of institutions. Do not include degrees or professional titles (e.g. Dr, Prof, etc,).

Text:

Leave a line between sections but do not indent.

Use standard abbreviations only. Within the body of the abstract, when using abbreviations spell out the name in full at the first mention and follow with the abbreviation in the parenthesis. Abbreviations may be used in the title, provided the name in full is outlined in the body of the abstract.

Keywords: add keywords that best matches with the content of the abstract.

ABSTRACT CONTENT GUIDELINES▼
  • Abstract content should be no more than one-page, inclusive blank spaces, and punctuation. The minimum size of the abstract is 750 characters. Abstracts exceeding the word limit will be returned for resubmission.
  • Abstracts must be submitted in clear English with accurate grammar and spelling of a quality suitable for publication.
  • The anstract should state the problem being addressed, main findings and principal conclusions. If necessary, references should be minimally cited in the body of the abstract.
  • Graphs and tables may be included in the abstract, provided they add value to the content and remain within the bounds of the template. Graphs/tables can be added as images (.jpg) or tables can be entered directly; max. 1 image can be added per abstract.
  • Compliance with the specifications is imperative. Any abstract that does not comply with these specifications will not be accepted for review and will be returned to you by the Conference Organizers for resubmission.
EVALUATION CRITERIA AND REVIEW PROCESS▼

Abstracts will be independently reviewed and scored by a minimum of 3 reviewers on November 9 –  November 19, using the following criteria:

  • Clearly written
  • Internally consistent
  • Indicates aims or hypothesis of the research/paper
  • Describes appropriate methods/methodology
  • Describes relevant results/describes main findings
  • Draws valid conclusions from results/findings
  • Is relevant to the Conference audience

Reviewer scores and comments will be strongly considered when developing the Conference program and offering presentation slots.

POLICIES & REQUIREMENTS ▼

GENERAL POLICIES & REQUIREMENTS FOR THE SUBMISSION OF ABSTRACTS
‘Encore’ abstracts previously accepted for presentation and/or publication are also accepted. In this case, authors must supply information regarding the original presentation, indicating the name of the meeting and publication number.

Abstracts containing updated data may also be submitted to INMC 2019. In this case, additional information must be given specifying clearly which new data will be presented, for example, the final analysis of primary endpoint(s) or intermediate statistical analysis. Authors must at the same time also supply information regarding the original presentation for identification and comparison purposes, indicating the name of the meeting, year and publication number. Violation of this policy will result in a rejection of the submitted abstract.

Should any similarities to prior presentations or publications exist, these must be explained in a covering letter, citing the INMC 2019 abstract submission number, title and first author, to the INMC Program Manager by e-mail.

All abstracts must be prepared according to the guidelines provided. Submissions will be returned to the author without review if not in the correct format and must be resubmitted immediately in the correct format to be reviewed and considered for inclusion in the program.

The presenting author only must submit the abstract.

The presenting author will be required to register and pay for the conference to ensure their abstract(s) are included in the final program and abstract publication. Deadline for author registration is December 14, 2018.

Do not resubmit an abstract for any reason other than a notified submission error. If you do not receive a confirmation email with a receipt number confirming that your abstract was successfully uploaded, please contact the Conference Secretariat at info@nano-innovate.com.

It is the responsibility of the presenting author to ensure that the abstract is submitted correctly. After an author has submitted an abstract, he/she must check the submission, which will be converted to a PDF file, to ensure the document has been uploaded correctly.

Abstracts will be reviewed by the appointed Conference Abstract Reviewers.

Faxed or mailed hard-copy abstracts or abstracts sent on disc/CD will not be accepted. If you are unable to submit via the website, please contact the Conference Secretariat by email: info@nano-innovate.com.

DISCLAIMER REGARDING THE SUBMISSION OF ABSTRACTS
The Conference Organizers will not be held responsible for abstract submissions not received via the website or for submission errors caused by internet service outages, hardware or software delays, power outages or unforeseen events.

 


 

ABSTRACT SUBMISSION INSTRUCTIONS

Please read through the submission instructions below before preparing your abstract.

Step 1: Read the General Policies and Requirements for the submission of abstracts.

Step 2: Write your abstract, following the Abstract Guidelines.

Step 3: Select which Track & Theme best relates to your abstract.

Step 4: Review the Evaluation Criteria and Review Process for abstracts (below).

Step 5: Save your abstract text as a document on your computer. Abstracts must not exceed 4,500 characters.

Step 6: Click the Abstract Submission button above to enter the Abstract Submission Form. It will be necessary to copy/paste the Microsoft Word copy of your abstract and add the author details.

 

 

CONTACT US

Congress Secretariat
MCI Group Canada
#200 - 1444 Alberni Street
Vancouver, BC Canada V6G 2Z4
Email: info@nano-innovate.com 
Tel: +1 604 909 1286

Info subject to change without notice.